Morphic Holding Corp (MORF) Value Adjusted for Debt and Cash

Morphic Holding Corp - graphic logo of issuer MORF

Morphic Holding, Inc. (MORF) is establishing close partnerships with CDMO contractors to launch mass production of drugs, creating redundant capacities. Business growth is fueled by a merger with Eli Lilly and the development of an innovative oral treatment for Crohn's disease. The company's pricing evolution, where the Enterprise Value equals , reflects the specifics of a model based on the full delegation of synthesis and testing to external laboratories.

MORF (morphictx.com) Total Company Value history from 07/04/2022 to 10/28/2026

Morphic Holding, Inc. (MORF) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Morphic Therapeutic|MORF - Price Target Chart
- market capitalization data:
Market Value Morphic|MORF - Enterprise Value
- book capitalization data:
Share Book Value Morphic|MORF - Company Book Value|Market Capitalization to Net Assets morphictx.com|MORF - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Morphic Holding, Inc.|MORF - Long-Term Debt to Capital|Short-Term Debt to Capital morphictx.com|MORF - Company Debts|Debt to Net Assets Ratio Morphic|MORF - Company Long-Term Debt|Company Current Liabilities Morphic
Comprehensive company analysis:Morphic Therapeutic (MORF)
Original product of Morphic Holding, Inc.

The selection of the issuer is based on a multiples analysis, where the key metric is the calculation of the total business buyout cost via the sum of market capitalization and debt minus liquid assets. For Morphic Holding, Inc. (MORF), which is developing innovative oral drugs for intestinal inflammation, the total capital indicator reflects the market acquisition price of the company, accounting for its debt load during an active growth phase.

Competitor analysis for Morphic Holding, Inc.

Phathom Pharma - Total Enterprise Value|Total Company Value Terns Pharmaceuticals Inc (TERN)|IRWD - Value Adjusted for Debt and Cash|Enterprise Value curanexpharma.com (CURX)|IMRN (Immuron) - Full Business Value|Total Company Value Evoke Pharma EVOK|Full Business Value Entero|RedHill Biopharma (RDHL) - Enterprise Value|Value Adjusted for Debt and Cash Palisade Bio Inc. (PALI)|Enterprise Value JAGX (Jaguar Health, Inc.)|bioratherapeutics.com - Enterprise Value